RE:RE:RE:hope there is no more news releases I don't have a problem with the limited information with Q2 scheduled for February as long as they elaborate on this news at Q2 and the revenues have substantially increased.
14 to 16 and the 2 million Ebitda and clarity regarding their plans moving forward I believe could trigger interest with the market. Beena is a seasoned and as far as can tell credible and respected individual within the business community, therefore if Supreme can start showing significant improvement relating to revenues, maintain losses in check I can definitely see institutional investors taking a closer look.
I'll say this again, they have to deliver to gain credibility. All the DD I've done regarding the board and management team supports the belief they have a solid foundation when talking about management, therefore I believe all the shares issued in December was for a reason.
On paper the company seems to be on solid ground, but without substantially increasing revenue it could a long couple of months waiting for Q3. IMHO It's a penny stock, if the market and institutional investors can start showing interest it wouldn't be long before Supreme start closing the gap with its competitors which should be the likes of Organigram and Hexo, but as long as we show meager numbers we'll be competing the companies on life support.
Beena is right when she says numbers dictates the trajectory of a company, but at the penny level I believe the blend of numbers and solid NRs is a must. IMO
I strongly believe there is money paying close attention to the company, waiting to see if it can deliver.